JNJ-67856633   Click here for help

GtoPdb Ligand ID: 11507

Synonyms: example 158 [WO2018119036] | JNJ67856633
Compound class: Synthetic organic
Comment: JNJ-67856633 is a selective, allosteric mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease inhibitor [1]. It was developed for antineoplastic potential.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 76.18
Molecular weight 320.09
XLogP 3.1
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=C)c1cnn(c1C(F)(F)F)c1cccc2c1cc[nH]c2=O
Isomeric SMILES NC(=C)c1cnn(c1C(F)(F)F)c1cccc2c1cc[nH]c2=O
InChI InChI=1S/C15H11F3N4O/c1-8(19)11-7-21-22(13(11)15(16,17)18)12-4-2-3-10-9(12)5-6-20-14(10)23/h2-7H,1,19H2,(H,20,23)
InChI Key JPUXFKNCQZIRSR-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
JNJ-67856633 has progressed to early clinical trial for CLL and non-Hodgkin lymphoma, either as monotherapy or in combination with a Janssen's BTK inhibitor JNJ-64264681.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04657224 A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Phase 1 Interventional Janssen Research & Development, LLC
NCT03900598 A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Phase 1 Interventional Janssen Research & Development, LLC